CD8A and neoplasm: Combined with an anti-CTLA-4 antibody, this therapy remodels the TME, reduces Tregs and MDSCs, and increases CD8+ T-cells and cytokines like IL-12 and IFN-γ, enhancing tumor cytotoxicity.